Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers

Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.

This multicenter non-interventional observational sample acquisition study is designed to acquire whole-blood samples from pregnant women who present with signs and symptoms of Pre-E and are in the care at an OB-GYN and/or Maternal Fetal Medicine (MFM) site, defined as outpatient centers, clinic sites, and medical offices.

Study population includes subjects who are pregnant, of any race or ethnicity, 18 to 45 years of age, 28 0/7 to 36 6/7 weeks' gestational age with a singleton fetus and have provided written informed consent to provide whole blood specimens at one or more study visits.

Inclusion Criteria:

• Subject is 18 to 45 years of age

• Subject is willing to provide informed consent

• Subject enrolling at a study OB-GYN or MFM site is in the opinion of the physician able to provide 20 mL of whole blood and will comply with all study procedures

• Subject has a singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using 2014 ACOG Dating Criteria (pregnancies starting as twins but complicated with either vanishing twin syndrome or fetal demise of one twin before 14 weeks, are eligible for inclusion)

• Patient presenting with clinical suspicion of Pre-E based on one or more of the following clinical signs and symptoms of Pre-E:

  • New onset increased blood pressure in otherwise normotensive patient
  • Worsening hypertension in a patient with pre-existing hypertension
  • New onset proteinuria or worsening of pre-existing proteinuria
  • Any other clinical finding typically associated with suspicion of Pre-E and requiring workup to rule-out Pre-E

Exclusion Criteria:

• Pregnancy is non-viable, as evidenced by absence of fetal cardiac activity
• Major fetal anomaly or chromosomal aneuploidy
• Current dialysis for kidney failure, including continuous ambulatory peritoneal dialysis